

Giancarlo Agnelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10426055/publications.pdf>

Version: 2024-02-01

339
papers

43,860
citations

6233

80
h-index

2071

204
g-index

346
all docs

346
docs citations

346
times ranked

21912
citing authors

#	ARTICLE	IF	CITATIONS
1	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 336-343.	2.3	6
2	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. <i>Thrombosis and Haemostasis</i> , 2022, 122, 796-807.	1.8	21
3	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	1.8	25
4	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. <i>Annals of Neurology</i> , 2022, 91, 78-88.	2.8	8
5	Contemporary clinical management of acute pulmonary embolism: the COPE study. <i>Internal and Emergency Medicine</i> , 2022, 17, 715-723.	1.0	4
6	Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. <i>Stroke</i> , 2022, 53, 1540-1549.	1.0	26
7	Medicine before and after David Cox. <i>European Journal of Internal Medicine</i> , 2022, 98, 1-3.	1.0	4
8	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. <i>European Journal of Cancer</i> , 2022, 165, 136-145.	1.3	11
9	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. <i>Stroke</i> , 2022, 53, 2620-2627.	1.0	28
10	Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. <i>Journal of Medical Economics</i> , 2022, 25, 840-847.	1.0	5
11	Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 987-993.	1.3	10
12	SMASH-U classification: a tool for aetiology-oriented management of patients with acute haemorrhagic stroke. <i>Internal and Emergency Medicine</i> , 2021, 16, 109-114.	1.0	13
13	Safety of catheter ablation of atrial fibrillation in cancer survivors. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 419-426.	0.6	20
14	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke. <i>JAMA Neurology</i> , 2021, 78, 177.	4.5	17
15	Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation. <i>Clinical Drug Investigation</i> , 2021, 41, 43-51.	1.1	18
16	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 616-624.	1.8	55
17	Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials. <i>International Journal of Stroke</i> , 2021, 16, 43-54.	2.9	4
18	Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence. <i>Life</i> , 2021, 11, 395.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead. <i>Thrombosis and Haemostasis</i> , 2021, 121, 700-702.	1.8	0
20	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021, 52, 1450-1454.	1.0	7
21	Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. <i>European Journal of Cancer</i> , 2021, 148, 371-381.	1.3	38
22	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. <i>Cancer Treatment Reviews</i> , 2021, 96, 102190.	3.4	14
23	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. <i>European Journal of Internal Medicine</i> , 2021, 88, 43-51.	1.0	10
24	Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2021, 42, 3190-3199.	1.0	40
25	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2751-2759.	1.9	18
26	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	0.7	18
27	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2801-2813.	1.9	19
28	Home management or hospital admission for low-risk pulmonary embolism? Clinical scores versus pragmatic assessment. <i>European Heart Journal</i> , 2021, 42, 3158-3160.	1.0	5
29	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2021, 174, 1420-1429.	2.0	60
30	Upper extremities deep vein thrombosis treated with oral direct anticoagulants: A prospective cohort study. <i>International Journal of Cardiology</i> , 2021, 339, 158-163.	0.8	10
31	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102280.	3.4	10
32	Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. <i>Thrombosis Research</i> , 2021, 208, 138-144.	0.8	6
33	The high-risk bleeding category of different scores in patients with venous thromboembolism: Systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 94, 45-55.	1.0	5
34	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2021, 0, .	1.8	3
35	Learning in times of stress: Lessons from COVID-19 that will last throughout this century. <i>European Journal of Internal Medicine</i> , 2021, , .	1.0	1
36	341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
37	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. <i>Haematologica</i> , 2021, , .	1.7	0
38	Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients. <i>Haematologica</i> , 2020, 105, 838-848.	1.7	21
39	Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 251-258.	1.0	16
40	Lacunar stroke syndromes as predictors of lacunar and non-lacunar infarcts on neuroimaging: a hospital-based study. <i>Internal and Emergency Medicine</i> , 2020, 15, 429-436.	1.0	6
41	Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. <i>Atherosclerosis</i> , 2020, 293, 94-100.	0.4	109
42	Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study. <i>International Journal of Cardiology</i> , 2020, 301, 167-172.	0.8	23
43	Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. <i>European Journal of Internal Medicine</i> , 2020, 72, 53-59.	1.0	8
44	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020, 82, 48-55.	1.0	5
45	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , 2020, 196, 297-304.	0.8	5
46	Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management. <i>European Journal of Internal Medicine</i> , 2020, 82, 18-20.	1.0	7
47	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020, 51, 3504-3513.	1.0	67
48	PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients – PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2020, 83, 566-575.	0.6	5
49	A nomogram to predict unfavourable outcome in patients receiving oral anticoagulants for atrial fibrillation after stroke. <i>European Stroke Journal</i> , 2020, 5, 384-393.	2.7	5
50	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020, 5, 374-383.	2.7	6
51	Definition of major bleeding: Prognostic classification. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2852-2860.	1.9	21
52	Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. <i>Thrombosis Research</i> , 2020, 191, S123-S127.	0.8	1
53	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	2.2	21
54	Diagnosis and Treatment of Deep Vein Thrombosis in the Emergency Department: Results of an Italian Nominal Group Technique Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095972.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1128-1136.	1.8	93
56	Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation. <i>Cerebrovascular Diseases Extra</i> , 2020, 10, 44-49.	0.5	5
57	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. <i>Thrombosis and Haemostasis</i> , 2020, 120, 692-701.	1.8	9
58	Acute hematoma expansion after spontaneous intracerebral hemorrhage: risk factors and impact on long-term prognosis. <i>Neurological Sciences</i> , 2020, 41, 2503-2509.	0.9	10
59	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1599-1607.	13.9	658
60	Prognostic value of respiratory index in haemodynamically stable patients with acute pulmonary embolism: The Respiratory Index model study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 286-292.	0.4	13
61	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2347-2354.	1.0	7
62	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. <i>European Journal of Internal Medicine</i> , 2020, 75, 35-43.	1.0	17
63	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	1.9	60
64	Acute treatment of venous thromboembolism. <i>Blood</i> , 2020, 135, 305-316.	0.6	29
65	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , 2020, 14, 998.	0.6	4
66	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. <i>Minerva Medica</i> , 2020, 111, 370-372.	0.3	0
67	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019, 4, 55-64.	2.7	4
68	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4363.	2.4	177
69	Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study. <i>TH Open</i> , 2019, 03, e157-e164.	0.7	1
70	Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 2043-2052.	1.8	4
71	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. <i>European Journal of Internal Medicine</i> , 2019, 69, 1-7.	1.0	5
72	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019, 42, 1147-1154.	0.7	16

#	ARTICLE	IF	CITATIONS
73	Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. <i>International Journal of Cardiology</i> , 2019, 281, 56-61.	0.8	23
74	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	1.9	30
75	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019, 50, 2093-2100.	1.0	29
76	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019, 50, 2168-2174.	1.0	59
77	Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1217-1228.	1.9	27
78	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 439-453.	1.0	20
79	Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation. <i>Data in Brief</i> , 2019, 23, 103794.	0.5	1
80	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. <i>Quality of Life Research</i> , 2019, 28, 2111-2124.	1.5	38
81	Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. <i>Annals of Neurology</i> , 2019, 85, 823-834.	2.8	84
82	Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the Letter to the Editor from Dr. Soriguet et al.. <i>International Journal of Cardiology</i> , 2019, 280, 97.	0.8	0
83	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
84	Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 781-783.	13.9	59
85	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
86	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 461-466.	1.8	11
87	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. <i>Quality of Life Research</i> , 2019, 28, 1155-1177.	1.5	9
88	Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. <i>Atherosclerosis</i> , 2018, 271, 177-181.	0.4	19
89	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. <i>Thrombosis Research</i> , 2018, 170, 181-191.	0.8	29
90	Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 391-394.	0.5	3

#	ARTICLE	IF	CITATIONS
91	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018, 16, 9.	0.9	15
92	Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?. <i>Thrombosis Research</i> , 2018, 164, S168-S171.	0.8	2
93	Cancer-associated ischemic stroke: A retrospective multicentre cohort study. <i>Thrombosis Research</i> , 2018, 165, 33-37.	0.8	45
94	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	1.0	267
95	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018, 23, 247-255.	1.9	63
96	Bedside sonography assessment of extravascular lung water increase after major pulmonary resection in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, 4077-4084.	0.6	10
97	Antithrombotic Cancer Associated Thrombosis: It May Change. <i>Journal of Blood & Lymph</i> , 2018, s1, .	0.0	0
98	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018, 7, e010133.	1.6	55
99	Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1063-1069.	1.0	4
100	The impact of co-morbidity on the disease burden of VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 507-515.	1.0	9
101	Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. <i>Thrombosis Research</i> , 2018, 170, 175-180.	0.8	31
102	Clinical skills or high-tech MR in TIA patients: what makes the difference?. <i>Neurological Sciences</i> , 2018, 39, 2091-2096.	0.9	2
103	Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. <i>International Journal of Cardiology</i> , 2018, 269, 75-79.	0.8	4
104	Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study. <i>International Journal of Cardiology</i> , 2018, 269, 152-157.	0.8	35
105	The complexity of patients hospitalized in Internal Medicine wards evaluated by FADOI-COMPLIMED score(s). A hypothetical approach. <i>PLoS ONE</i> , 2018, 13, e0195805.	1.1	14
106	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1668-1678.	1.8	121
107	Alcohol intake and the risk of intracerebral hemorrhage in the elderly. <i>Neurology</i> , 2018, 91, e227-e235.	1.5	20
108	Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial. <i>Blood Transfusion</i> , 2018, 16, 387-391.	0.3	12

#	ARTICLE	IF	CITATIONS
109	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. <i>European Respiratory Journal</i> , 2017, 49, 1601732.	3.1	9
110	Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 236, 363-369.	0.8	27
111	Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017, 34, 620-637.	1.3	8
112	Acute Pulmonary Embolism after Discharge: Duration of Therapy and Follow-up Testing. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 094-106.	0.8	3
113	Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1363-1368.	0.7	7
114	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema. <i>Stroke</i> , 2017, 48, 726-732.	1.0	32
115	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in) <i>TJ ETQq1 1 0.784314 rgt /Overl</i>	0.7	31
116	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. <i>ESMO Open</i> , 2017, 2, e000188.	2.0	29
117	Risk of death in patients with major bleedings while on treatment with oral anticoagulants. <i>International Journal of Cardiology</i> , 2017, 235, 200.	0.8	0
118	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. <i>International Journal of Cardiology</i> , 2017, 227, 261-266.	0.8	47
119	The year in cardiology 2016: peripheral circulation. <i>European Heart Journal</i> , 2017, 38, ehw643.	1.0	6
120	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, 016950.	0.8	6
121	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 527-535.	1.0	9
122	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 1291-1305.	1.0	23
123	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. <i>Thrombosis Research</i> , 2017, 157, 181-188.	0.8	10
124	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin K Oral Anticoagulants (RAF-NOACs) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	89
125	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) <i>TJ ETQq1 1 0.784314 rgt /Overl</i>	1.7	43
126	The management of acute venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1326-1337.	1.8	74

#	ARTICLE	IF	CITATIONS
127	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017, 1, p1x009.	1.4	6
128	Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes. <i>Internal and Emergency Medicine</i> , 2017, 12, 573-576.	1.0	1
129	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 809-816.	1.8	16
130	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1159-1164.	1.8	16
131	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. <i>European Journal of Internal Medicine</i> , 2016, 33, 42-46.	1.0	14
132	Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 924-929.	0.9	33
133	Risk stratification and management of acute pulmonary embolism. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 404-412.	0.9	26
134	Treatment of Venous Thromboembolism With New Anticoagulant Agents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1941-1955.	1.2	63
135	Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 336-339.	1.0	17
136	Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter?. <i>Internal and Emergency Medicine</i> , 2016, 11, 817-824.	1.0	11
137	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. <i>European Respiratory Journal</i> , 2016, 48, 780-786.	3.1	199
138	The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry. <i>Internal and Emergency Medicine</i> , 2016, 11, 1095-1102.	1.0	5
139	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 410-416.	1.8	39
140	Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKa). <i>Thrombosis and Haemostasis</i> , 2016, 116, 349-355.	1.8	28
141	Reply to Letter. <i>Annals of Surgery</i> , 2016, 263, e63.	2.1	1
142	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT. <i>Chest</i> , 2016, 149, 192-200.	0.4	76
143	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 32-67.	1.0	243
144	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016, 263, 231-237.	1.8	32

#	ARTICLE	IF	CITATIONS
145	Predictors of Venous Thromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016, 128, 1422-1422.	0.6	1
146	The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry. <i>Thrombosis Journal</i> , 2015, 13, 41.	0.9	40
147	Reply to Letter. <i>Annals of Surgery</i> , 2015, 262, e123-e124.	2.1	1
148	Direct Oral Anticoagulants in Patients With VTE and Cancer. <i>Chest</i> , 2015, 147, 475-483.	0.4	253
149	Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. <i>Haematologica</i> , 2015, 100, e35-e38.	1.7	20
150	Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No. <i>Internal and Emergency Medicine</i> , 2015, 10, 281-284.	1.0	1
151	Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach. <i>European Respiratory Journal</i> , 2015, 45, 1142-1149.	3.1	21
152	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2175-2182.	1.0	213
153	Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 113-132.	1.5	7
154	Venous thrombosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15006.	18.1	216
155	Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. <i>Internal and Emergency Medicine</i> , 2015, 10, 595-601.	1.0	12
156	Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2015, 10, 555-560.	1.0	11
157	Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2015, 10, 651-656.	1.0	19
158	Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. <i>Thrombosis Research</i> , 2015, 136, 924-927.	0.8	39
159	Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. <i>Journal of Neurology</i> , 2015, 262, 459-468.	1.8	43
160	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2014, 9, 559-67.	1.0	27
161	Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use). <i>Current Vascular Pharmacology</i> , 2014, 12, 351-352.	0.8	0
162	Antithrombotic medications and the etiology of intracerebral hemorrhage. <i>Neurology</i> , 2014, 82, 529-535.	1.5	32

#	ARTICLE	IF	CITATIONS
163	Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: A meta-analysis. <i>Thrombosis Research</i> , 2014, 134, 1265-1271.	0.8	47
164	Acute Stroke Symptoms: Do Differences Exist between Sexes?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2928-2933.	0.7	10
165	A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer. <i>Annals of Surgery</i> , 2014, 259, 665-669.	2.1	162
166	Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery. <i>Annals of Surgery</i> , 2014, 259, 1073-1079.	2.1	30
167	Lung ultrasound in the diagnosis of stroke-associated pneumonia. <i>Internal and Emergency Medicine</i> , 2014, 9, 173-178.	1.0	14
168	96Âhours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack. <i>Internal and Emergency Medicine</i> , 2014, 9, 65-67.	1.0	28
169	Aspirin for prevention and treatment of venous thromboembolism. <i>Blood Reviews</i> , 2014, 28, 103-108.	2.8	46
170	Edoxaban: a focused review of its clinical pharmacology. <i>European Heart Journal</i> , 2014, 35, 1844-1855.	1.0	99
171	Efficacy and safety of direct oral anticoagulants after pulmonary embolism: A meta-analysis. <i>International Journal of Cardiology</i> , 2014, 177, 601-603.	0.8	16
172	Neuroimaging in Intracerebral Hemorrhage. <i>Stroke</i> , 2014, 45, 903-908.	1.0	113
173	Aspirin for the Prevention of Recurrent Venous Thromboembolism. <i>Circulation</i> , 2014, 130, 1062-1071.	1.6	232
174	Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. <i>European Respiratory Journal</i> , 2014, 43, 1678-1690.	3.1	144
175	Thromboprophylaxis in Acutely Ill Medical Patients: Results of A Survey Among Italian Physicians. <i>Thrombosis Research</i> , 2014, 134, 572-577.	0.8	5
176	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
177	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	13.9	1,221
178	New strategies of VTE prevention in cancer patients. <i>Thrombosis Research</i> , 2014, 133, S128-S132.	0.8	9
179	The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?. <i>Blood</i> , 2014, 124, 155-156.	0.6	17
180	New oral anticoagulants for the treatment ofÂvenous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 151-161.	0.7	19

#	ARTICLE	IF	CITATIONS
181	Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. <i>Internal and Emergency Medicine</i> , 2013, 8, 575-580.	1.0	11
182	Severity of acute intracerebral haemorrhage, elderly age and atrial fibrillation: Independent predictors of poor outcome at three months. <i>European Journal of Internal Medicine</i> , 2013, 24, 310-313.	1.0	21
183	Apixaban for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 699-708.	13.9	1,116
184	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 799-808.	13.9	1,915
185	Obesity and the Risk of Intracerebral Hemorrhage. <i>Stroke</i> , 2013, 44, 1584-1589.	1.0	46
186	Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 471-477.	0.9	20
187	Acute Pulmonary Embolism: External Validation of an Integrated Risk Stratification Model. <i>Chest</i> , 2013, 144, 1539-1545.	0.4	71
188	Symptoms and clinical relevance: A dilemma for clinical trials on prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 109, 585-588.	1.8	12
189	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2012, 366, 1287-1297.	13.9	2,080
190	Systemic Thrombolysis in Patients With Acute Ischemic Stroke and Internal Carotid ARtery Occlusion. <i>Stroke</i> , 2012, 43, 125-130.	1.0	86
191	Multidetector CT Scan for Acute Pulmonary Embolism. <i>Chest</i> , 2012, 142, 1417-1424.	0.4	90
192	New and old anticoagulants in cancer. <i>Thrombosis Research</i> , 2012, 129, S101-S105.	0.8	15
193	Admission Leukocytosis in Acute Cerebral Ischemia: Influence on Early Outcome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 819-824.	0.7	44
194	Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 601-609.	13.9	489
195	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. PiÅ¹ luci che ombre. <i>Italian Journal of Medicine</i> , 2012, 6, 153-169.	0.2	0
196	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. <i>Thrombosis Research</i> , 2012, 129, 392-400.	0.8	56
197	Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry. <i>Thrombosis Research</i> , 2012, 130, 369-373.	0.8	33
198	Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). <i>Thrombosis Research</i> , 2012, 130, 847-852.	0.8	129

#	ARTICLE	IF	CITATIONS
199	Intravenous Thrombolysis for Acute Ischemic Stroke Associated to Extracranial Internal Carotid Artery Occlusion: The ICARO-2 Study. <i>Cerebrovascular Diseases</i> , 2012, 34, 430-435.	0.8	22
200	Aspirin for Preventing the Recurrence of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2012, 366, 1959-1967.	13.9	545
201	A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. <i>Internal and Emergency Medicine</i> , 2012, 7, 291-292.	1.0	299
202	Predictive value of admission blood glucose level on short-term mortality in acute cerebral ischemia. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 70-76.	1.2	25
203	D-Dimer for risk stratification in patients with acute pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 48-57.	1.0	61
204	Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome. <i>Journal of Neurology</i> , 2012, 259, 106-110.	1.8	32
205	Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 672.	0.5	0
206	Rivaroxaban. <i>Clinical Pharmacokinetics</i> , 2011, 50, 675-686.	1.6	301
207	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. <i>BMJ: British Medical Journal</i> , 2011, 342, d3036-d3036.	2.4	315
208	Non-neurological complications of acute stroke: frequency and influence on clinical outcome. <i>Internal and Emergency Medicine</i> , 2011, 6, 119-123.	1.0	17
209	Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. <i>Journal of Translational Medicine</i> , 2011, 9, 179.	1.8	90
210	Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. <i>European Heart Journal</i> , 2011, 32, 1657-1663.	1.0	188
211	Risk of Recurrent Cerebrovascular Events in Patients with Cryptogenic Stroke or Transient Ischemic Attack and Patent Foramen Ovale: The FORI (Foramen Ovale Registro Italiano) Study. <i>Cerebrovascular Diseases</i> , 2011, 31, 109-116.	0.8	43
212	Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i> , 2010, 5, 281-290.	1.0	14
213	Right ventricle dysfunction in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2010, 5, 453-455.	1.0	11
214	New anticoagulants for the prevention of venous thromboembolism. <i>Drug Design, Development and Therapy</i> , 2010, 4, 49.	2.0	23
215	Gender Differences in Patients with Acute Ischemic Stroke. <i>Women's Health</i> , 2010, 6, 51-57.	0.7	54
216	Acute Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2010, 363, 266-274.	13.9	423

#	ARTICLE	IF	CITATIONS
217	Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. <i>Thrombosis Research</i> , 2010, 125, e82-e86.	0.8	168
218	Thromboprophylaxis during chemotherapy in patients with advanced cancer. <i>Thrombosis Research</i> , 2010, 125, S17-S20.	0.8	16
219	Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. <i>Atherosclerosis</i> , 2010, 212, 564-566.	0.4	37
220	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2010, 363, 2499-2510.	13.9	2,807
221	Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. <i>Thrombosis and Haemostasis</i> , 2009, 101, 596-598.	1.8	6
222	Acute Hyperglycemia and Early Hemorrhagic Transformation in Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2009, 28, 119-123.	0.8	74
223	The Concept of Ischemic Penumbra in Acute Stroke and Therapeutic Opportunities. <i>European Neurology</i> , 2009, 61, 321-330.	0.6	120
224	Seasonal Variation in the Occurrence of Venous Thromboembolism: Data From the MASTER Registry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 309-315.	0.7	35
225	Low Levels of Low-Density Lipoprotein Cholesterol Increase Hemorrhagic Transformation but Not Parenchymal Hematoma in Large Artery Atherothrombosis. <i>Stroke</i> , 2009, 40, e544; author reply e545.	1.0	8
226	Attitudes to prescribing compression stockings for patients with acute dvt: the MASTER registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 389-393.	1.0	9
227	Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISST). <i>Thrombosis Research</i> , 2009, 124, e26-e31.	0.8	20
228	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology</i> , The, 2009, 10, 943-949.	5.1	538
229	Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2009, 150, 577.	2.0	209
230	Treatment of DVT: how long is enough and how do you predict recurrence. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 37-44.	1.0	58
231	Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. <i>Internal and Emergency Medicine</i> , 2008, 3, 117-122.	1.0	106
232	Need for extensive diagnostic work-up for patients with lacunar stroke. <i>Journal of Neurology</i> , 2008, 255, 637-642.	1.8	20
233	Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.	1.0	2,645
234	Antithrombotic Therapy for Venous Thromboembolic Disease. <i>Chest</i> , 2008, 133, 454S-545S.	0.4	1,860

#	ARTICLE	IF	CITATIONS
235	The MASTER registry on venous thromboembolism: Description of the study cohort. <i>Thrombosis Research</i> , 2008, 121, 605-610.	0.8	79
236	Clinical Benefit of Early Anticoagulation in Cardioembolic Stroke. <i>Cerebrovascular Diseases</i> , 2008, 25, 289-296.	0.8	12
237	Intravenous Thrombolysis with rt-PA in Acute Ischemic Stroke Patients Aged Older than 80 Years in Italy. <i>Cerebrovascular Diseases</i> , 2008, 25, 129-135.	0.8	57
238	Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. <i>Haematologica</i> , 2008, 93, 273-278.	1.7	123
239	Diagnosis and prognosis of acute pulmonary embolism: focus on serum troponins. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 339-349.	1.5	13
240	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einsteinâ€“DVT Dose-Ranging Study. <i>Blood</i> , 2008, 112, 2242-2247.	0.6	316
241	Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome. <i>Stroke</i> , 2008, 39, 2249-2256.	1.0	416
242	Response to Letter by Guedes and Ferro. <i>Stroke</i> , 2008, 39, .	1.0	0
243	Risk factors for venous thromboembolism in the elderly: results of the master registry. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 663-667.	0.5	25
244	Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. <i>Thrombosis and Haemostasis</i> , 2008, 99, 978-980.	1.8	15
245	A commentary: To screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. <i>Thrombosis and Haemostasis</i> , 2008, 99, 241-244.	1.8	18
246	A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study. <i>Blood</i> , 2008, 112, 6-6.	0.6	25
247	Epidemiology of Cerebral Vein and Sinus Thrombosis. , 2007, 23, 16-22.		32
248	Effect of On-Admission Antiplatelet Treatment on Patients with Cerebral Hemorrhage. <i>Cerebrovascular Diseases</i> , 2007, 24, 215-218.	0.8	43
249	Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939). <i>Circulation</i> , 2007, 116, 180-187.	1.6	324
250	Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke. <i>Stroke</i> , 2007, 38, 423-430.	1.0	286
251	Endothelial dysfunction in patients with spontaneous venous thromboembolism. <i>Haematologica</i> , 2007, 92, 812-818.	1.7	92
252	Venous thromboembolism (VTE) in Europe. <i>Thrombosis and Haemostasis</i> , 2007, 98, 756-764.	1.8	1,100

#	ARTICLE	IF	CITATIONS
253	What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?. <i>Thrombosis Research</i> , 2007, 119, 265-274.	0.8	82
254	Thromboprophylaxis during chemotherapy after advanced cancer. <i>Thrombosis Research</i> , 2007, 120, S128-S132.	0.8	8
255	Prognostic Value of Troponins in Acute Pulmonary Embolism. <i>Circulation</i> , 2007, 116, 427-433.	1.6	653
256	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , 2007, 28, 1717-1722.	1.0	121
257	Statins and Stroke Prevention. <i>Cerebrovascular Diseases</i> , 2007, 24, 170-182.	0.8	61
258	The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. <i>Journal of Surgical Oncology</i> , 2007, 96, 265-272.	0.8	21
259	Clinically Overt Venous Thromboembolism after Urologic Cancer Surgery: Results from the @RISTOS Study. <i>European Urology</i> , 2007, 51, 130-136.	0.9	55
260	Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.. <i>Blood</i> , 2007, 110, 309-309.	0.6	4
261	Determinants of outcome in patients eligible for thrombolysis for ischemic stroke. <i>Vascular Health and Risk Management</i> , 2007, 3, 749-54.	1.0	13
262	Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. <i>Thrombosis and Haemostasis</i> , 2007, 98, 756-64.	1.8	531
263	Initial treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 96, 242-250.	1.8	13
264	Incidence of Chronic Thromboembolic Pulmonary Hypertension After a First Episode of Pulmonary Embolism. <i>Chest</i> , 2006, 130, 172-175.	0.4	377
265	Association of Persistent Right Ventricular Dysfunction at Hospital Discharge After Acute Pulmonary Embolism With Recurrent Thromboembolic Events. <i>Archives of Internal Medicine</i> , 2006, 166, 2151.	4.3	101
266	A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery. <i>Annals of Surgery</i> , 2006, 243, 89-95.	2.1	595
267	Assessment of Bleeding after Concomitant Administration of Antiplatelet and Anticoagulant Agents in Lower Limb Arthroplasty. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 428-434.	0.5	6
268	New Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 793-802.	1.5	11
269	Therapy Insight: venous-catheter-related thrombosis in cancer patients. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 214-222.	4.3	40
270	Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. <i>British Journal of Haematology</i> , 2005, 129, 811-817.	1.2	134

#	ARTICLE	IF	CITATIONS
271	Direct Thrombin Inhibitors for the Prevention of Venous Thromboembolism after Major Orthopaedic Surgery. <i>Current Pharmaceutical Design</i> , 2005, 11, 3885-3891.	0.9	9
272	Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 4057-4062.	0.8	293
273	Outcome in Patients with Stroke Associated with Internal Carotid Artery Occlusion. <i>Cerebrovascular Diseases</i> , 2005, 20, 108-113.	0.8	81
274	Current Issues in Anticoagulation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 2-9.	0.5	23
275	A prospective study on cardiovascular events after acute pulmonary embolism. <i>European Heart Journal</i> , 2005, 26, 77-83.	1.0	168
276	Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. <i>Thrombosis Research</i> , 2005, 116, 301-306.	0.8	52
277	Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery. <i>Clinical Drug Investigation</i> , 2005, 25, 65-77.	1.1	17
278	A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR.. <i>Blood</i> , 2005, 106, 278-278.	0.6	17
279	Thrombosis and cancer: clinical relevance of a dangerous liaison. <i>Haematologica</i> , 2005, 90, 154-6.	1.7	14
280	Long-term therapy of pulmonary embolism. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005, 6, 824-9.	0.1	0
281	Recurrent Venous Thromboembolism in Men and Women. <i>New England Journal of Medicine</i> , 2004, 351, 2015-2018.	13.9	33
282	Antithrombotic Therapy for Venous Thromboembolic Disease. <i>Chest</i> , 2004, 126, 401S-428S.	0.4	1,216
283	Prevention of Venous Thromboembolism in Surgical Patients. <i>Circulation</i> , 2004, 110, IV-4-IV-12.	1.6	207
284	Clinical Potential of Oral Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism. <i>Drugs</i> , 2004, 64, 47-52.	4.9	6
285	Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism. <i>Circulation</i> , 2004, 110, 744-749.	1.6	578
286	Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients. <i>Journal of Clinical Oncology</i> , 2003, 21, 3665-3675.	0.8	531
287	Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2003, 139, 19.	2.0	344
288	Critical Issues in Peripheral Arterial Disease Detection and Management <subtitle>A Call to Action</subtitle>. <i>Archives of Internal Medicine</i> , 2003, 163, 884.	4.3	486

#	ARTICLE	IF	CITATIONS
289	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. <i>Thrombosis and Haemostasis</i> , 2003, 89, 288-296.	1.8	256
290	Duration of Anticoagulant Treatment after Venous Thromboembolism. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 354-357.	0.5	0
291	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. <i>Thrombosis and Haemostasis</i> , 2003, 89, 288-96.	1.8	59
292	Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2002, 162, 2537.	4.3	124
293	Unresolved Issues in the Prevention and Treatment of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2002, 28, 033-040.	1.5	1
294	Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer. <i>New England Journal of Medicine</i> , 2002, 346, 975-980.	13.9	973
295	Novel approaches to the treatment of thrombosis. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 25-32.	4.0	67
296	Randomised, Double Blind, Multicentre, Placebo Controlled Study of Sulodexide in the Treatment of Venous Leg Ulcers. <i>Thrombosis and Haemostasis</i> , 2002, 87, 947-952.	1.8	79
297	Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. <i>Haematologica</i> , 2002, 87, 757-70.	1.7	13
298	Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. <i>New England Journal of Medicine</i> , 2001, 345, 165-169.	13.9	567
299	Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. <i>Seminars in Hematology</i> , 2001, 38, 58-66.	1.8	11
300	Risk Factors for Adverse Short-Term Outcome in Patients with Pulmonary Embolism. <i>Thrombosis Research</i> , 2001, 103, V239-V244.	0.8	19
301	Antithrombotic Therapy for Venous Thromboembolic Disease. <i>Chest</i> , 2001, 119, 176S-193S.	0.4	945
302	Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement. <i>Circulation</i> , 2001, 104, 74-78.	1.6	170
303	End Points in Studies on the Prevention of Deep Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2001, 27, 041-046.	1.5	6
304	Low-Molecular-Weight and Unfractionated Heparin for Prevention of Venous Thromboembolism in Neurosurgery. <i>Archives of Internal Medicine</i> , 2000, 160, 2327.	4.3	204
305	Short-Term Clinical Outcome of Patients With Acute Pulmonary Embolism, Normal Blood Pressure, and Echocardiographic Right Ventricular Dysfunction. <i>Circulation</i> , 2000, 101, 2817-2822.	1.6	785
306	Prevention of Venous Thromboembolism. <i>Thrombosis Research</i> , 2000, 97, V49-V62.	0.8	37

#	ARTICLE	IF	CITATIONS
307	Dermatan Sulphate for the Prevention of Postoperative Venous Thromboembolism in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 1999, 82, 30-34.	1.8	64
308	Dermatan sulphate in patients with heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1999, 104, 87-89.	1.2	12
309	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. <i>American Journal of Cardiology</i> , 1998, 82, 1230-1235.	0.7	109
310	Enoxaparin plus Compression Stockings Compared with Compression Stockings Alone in the Prevention of Venous Thromboembolism after Elective Neurosurgery. <i>New England Journal of Medicine</i> , 1998, 339, 80-85.	13.9	522
311	Antithrombotic Therapy for Venous Thromboembolic Disease. <i>Chest</i> , 1998, 114, 561S-578S.	0.4	184
312	Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis. <i>Clinical Pharmacokinetics</i> , 1997, 32, 145-172.	1.6	11
313	Venous Thromboembolism and Cancer: a Two-Way Clinical Association. <i>Thrombosis and Haemostasis</i> , 1997, 78, 117-120.	1.8	46
314	Experimental Pharmacology of Hirunorm: a Novel Synthetic Peptide Thrombin Inhibitor. <i>Thrombosis and Haemostasis</i> , 1996, 76, 384-392.	1.8	9
315	Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis. <i>Thrombosis and Haemostasis</i> , 1996, 76, 0887-0892.	1.8	37
316	Non-Anticoagulant Actions of Glycosaminoglycans. , 1996, , 101-112.		0
317	Anticoagulation in the Prevention and Treatment of Pulmonary Embolism. <i>Chest</i> , 1995, 107, 39S-44S.	0.4	17
318	Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. <i>International Journal of Cardiology</i> , 1995, 49, S77-S87.	0.8	4
319	Clinical Outcome of Orthopaedic Patients with Negative Lower Limb Venography at Discharge. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1042-1044.	1.8	21
320	Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. <i>Circulation</i> , 1995, 92, 2819-2824.	1.6	32
321	Reduced Dose Bolus Alteplase vs Conventional Alteplase Infusion for Pulmonary Embolism Thrombolysis. <i>Chest</i> , 1994, 106, 718-724.	0.4	182
322	Plasma Thrombin Neutralization Assay: Pharmacokinetic Applications. <i>Seminars in Thrombosis and Hemostasis</i> , 1994, 20, 266-273.	1.5	3
323	Dermatan sulphate in heparin-induced thrombocytopenia. <i>Lancet, The</i> , 1994, 344, 1295-1296.	6.3	28
324	New strategies for enhancing the speed and rate of coronary reperfusion. <i>American Journal of Cardiology</i> , 1993, 72, G51-G58.	0.7	1

#	ARTICLE	IF	CITATIONS
325	Thrombolytic and Haemorrhagic Effects of Bolus Doses of Tissue-Type Plasminogen Activator and a Hybrid Plasminogen Activator with Prolonged Plasma Half-Life (K2tu-PA: CGP 42935). <i>Thrombosis and Haemostasis</i> , 1993, 70, 294-300.	1.8	14
326	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , 1993, 70, 443-447.	1.8	6
327	Bolus Thrombolysis in Venous Thromboembolism. <i>Chest</i> , 1992, 101, 172S-182S.	0.4	25
328	PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. <i>Journal of the American College of Cardiology</i> , 1992, 20, 520-526.	1.2	337
329	A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture. <i>Thrombosis and Haemostasis</i> , 1992, 67, 203-208.	1.8	90
330	Detection of Asymptomatic Deep Vein Thrombosis by Real-Time B-Mode Ultrasonography in Hip Surgery Patients. <i>Thrombosis and Haemostasis</i> , 1992, 68, 257-260.	1.8	32
331	Rationale for Bolus t-PA Therapy To Improve Efficacy and Safety. <i>Chest</i> , 1990, 97, 161S-167S.	0.4	50
332	The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits. <i>Thrombosis and Haemostasis</i> , 1990, 63, 204-207.	1.8	77
333	Optimal Dosage Regimens of Tissue-Type Plasminogen Activator. <i>Seminars in Thrombosis and Hemostasis</i> , 1987, 13, 160-162.	1.5	6
334	The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabbits. <i>Thrombosis Research</i> , 1985, 40, 769-777.	0.8	58
335	DESMOPRESSIN-INDUCED IMPROVEMENT OF ABNORMAL COAGULATION IN CHRONIC LIVER DISEASE. <i>Lancet</i> , The, 1983, 321, 645.	6.3	23
336	Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia?. <i>Thrombosis and Haemostasis</i> , 1981, 46, 572-572.	1.8	10
337	FACTOR-VII _{coag} KINETICS IN FACTOR-VII-CRM+AND FACTOR-VII-CKM-DEFICIENCIES. <i>British Journal of Haematology</i> , 1980, 46, 307-309.	1.2	3
338	Thrombolysis for the Treatment of Pulmonary Embolism. , 0, , 503-512.		0
339	Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows. <i>Italian Journal of Medicine</i> , 0, , .	0.2	3